Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
28 juin 2024 09h00 HE
|
Elicio Therapeutics Inc.
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Announces Proposed Public Offering
27 juin 2024 16h05 HE
|
Elicio Therapeutics Inc.
BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
27 juin 2024 16h01 HE
|
Elicio Therapeutics Inc.
BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
05 févr. 2024 08h30 HE
|
Elicio Therapeutics Inc.
BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
25 janv. 2024 09h00 HE
|
Elicio Therapeutics Inc.
Published data shows lymph node-targeted Amphiphile (“AMP”)-peptide and CpG combination with TCR-T cell therapy led to complete eradication and durable responses against established murine solid...
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
17 janv. 2024 08h30 HE
|
Elicio Therapeutics Inc.
AMPLIFY-7P study builds on preliminary positive findings from the 2-peptide formulation of ELI-002 published in Nature Medicine demonstrating tumor biomarker reduction, with strong T cell responses...
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
16 janv. 2024 08h30 HE
|
Elicio Therapeutics Inc.
BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
11 janv. 2024 08h30 HE
|
Elicio Therapeutics Inc.
The 7-peptide formulation of ELI-002 is designed to stimulate an immune response against seven KRAS mutations that drive 25% of all solid tumors, potentially defeating resistance mechanismsElicio will...
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
09 janv. 2024 06h00 HE
|
Elicio Therapeutics Inc.
Data showed ELI-002 administered as a monotherapy induced robust, polyfunctional and durable KRAS specific CD4+ and CD8+ T cell responses Tumor biomarker reduction was observed in 84% of patients...
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
22 déc. 2023 09h00 HE
|
Elicio Therapeutics Inc.
BOSTON, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...